Navigation Links
Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes

Study Demonstrates Improvement of Accuracy with New Biosensor

FRANKLIN, Mass., Nov. 19 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes. Echo's non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and its Prelude SkinPrep System, which incorporates leading-edge, needle-free, controlled skin ablation. Echo's Symphony tCGM System is designed to provide patients with diabetes and critical care patients with a reliable, affordable, and easy-to-use, needle-free continuous glucose monitoring device. The purpose of the study was to test the performance of its new, improved one-piece, cost-effective and easy-to-use biosensor.

"This study represents another major step forward in our Symphony development program," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We believe that we have successfully developed a new cost-effective, one-piece biosensor and, with this study, we have demonstrated improvement in the accuracy of our Symphony system glucose readings. Data from this study demonstrates that Symphony, using the new, improved, cost-effective biosensor, is safe, accurate and reliable at monitoring glucose levels. We look forward to continued progress with our Symphony development program throughout this year and next as we move toward our goal of making Symphony available to patients."

Study Design

After Prelude skin ablation, ten (10) Symphony tCGM biosensors were applied to subjects with Type 1 or Type 2 Diabetes. Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300STAT PLUS laboratory analyzer. At the conclusion of the 24-hour study period, the test skin sites were inspected for redness or any other undesirable effects.

Analytical Methods

CGM performance is evaluated with multiple analytical tools, as defined by the Clinical and Laboratory Standards Institute's POCT05-A guideline. The primary metric, used to evaluate clinical accuracy, is the continuous glucose-error grid analysis (CG-EGA). The CG-EGA is a categorization of all data pairs based on the clinical significance of the accuracy. Accurate readings result in the same clinical decision when based on the CGM trend vs. the underlying blood glucose fluctuations. Benign errors lead to the same clinical outcome as accurate readings even though the actual clinical decision may differ. Erroneous readings lead to clinical errors. CGM performance is measured as the sum of accurate readings and benign errors. Numerical accuracy is the other key method for evaluating CGM performance. The most widely accepted tool is mean absolute relative difference (MARD). MARD is a standard error calculation tool that is used to measure the average absolute value of the relative (or percentage) difference between two measurements.

Study Results

Using approximately 900 Symphony tCGM glucose readings paired with reference blood glucose measurements, CG-EGA revealed that the accuracy of the Echo's Symphony tCGM System, measured as a percentage of accurate readings and benign errors, was 97%. The MARD for the study was 12.89%. There were no adverse events reported from the Prelude skin permeation or the Symphony tCGM biosensor.

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in acute and critical care. Echo's non-invasive Symphony tCGM System consists of its Prelude SkinPrep System, which incorporates patented and leading-edge skin ablation control technology, and wireless transmission and proprietary transdermal biosensor technologies. Echo's Symphony tCGM System is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin ablation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

10 Forge Parkway

Franklin, MA 02038, USA

Tel: 1+ 877-476-6878

Fax: 1+ 508-553-8760

© 2002 - 2009 Echo Therapeutics, Inc. All rights reserved worldwide.

    For More Information:
    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer

SOURCE Echo Therapeutics, Inc.

SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
2. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
3. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
4. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
6. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
7. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
8. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
9. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA Pharma ... EPIX ) announced today that the first patient has ... EPI-506 as a treatment for metastatic castration-resistant prostate cancer ... and Canada.  --> the United ... In the Phase 1/2 clinical trial, ESSA intends to ...
(Date:11/24/2015)... New York , 24. November 2015 ... des Avery Breathing Pacemaker Systems, ist erfreut, ... als Clinical Consultant bekannt geben zu können. ...   --> Foto ... Stockholm (Schweden). Von 1984-1986 war ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... , ... In response to recent news highlighting Oxycodone fraud, Novus Medical Detox ... United States grew 400 percent between 1999 and 2010, far more than the combined ... of all fatal drug overdoses. (1) , While oxycodone and the extended release form ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the ... and hit their goal of $20,000 in under 10 hours. , The ... new PRO Weight Loss Vest to the market. , The PRO Vest provides consumers with ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir ... customer service: the TrustDale certification. The award recognizes good companies for excellence in ... , tile and grout, and hard surface restoration company earned this recognition after ...
(Date:11/24/2015)... ... 24, 2015 , ... Dr. Kevin Day, local family chiropractor in Warsaw ... this holiday season. During the Indiana winter months, Vitamin D deficiency can lead ... at AlignLife want to help provide the tools needed to combat it this year! ...
Breaking Medicine News(10 mins):